Soleno Therapeutics (SLNO) Interest Expenses (2013 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Interest Expenses of $27.2 million for Q1 2026, up 1902.13% year-over-year from $1.4 million in Q1 2025, and up 1919.94% quarter-over-quarter from $1.3 million in Q4 2025.
Soleno Therapeutics (SLNO) Interest Expenses (2013 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Interest Expenses for 13 consecutive years, with $27.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 1902.13% year-over-year to $27.2 million; the TTM figure through Mar 2026 stood at $27.2 million (up 1669.42% YoY), while the FY2025 annual figure was $79.9 million, down 4.31% from the prior year.
- Interest Expenses rose to $27.2 million in Q1 2026 per SLNO's latest filing, from $1.3 million in the prior quarter.
- Across five years, Interest Expenses topped out at $170.6 million in Q2 2025 and bottomed at -$17000.0 in Q4 2024.
- Historically, Interest Expenses has averaged $39.2 million across 5 years, with a median of $1.4 million in 2025.
- On a YoY basis, Interest Expenses climbed as much as 13182982.71% in 2024 and fell as far as 122.08% in 2024.
- Soleno Therapeutics' Interest Expenses stood at $57.0 million in 2022, then sank by 99.86% to $77000.0 in 2023, then tumbled by 122.08% to -$17000.0 in 2024, then surged by 8035.29% to $1.3 million in 2025, then jumped by 1919.94% to $27.2 million in 2026.
- Business Quant data shows SLNO's Interest Expenses at $27.2 million in Q1 2026, $1.3 million in Q4 2025, and $113.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | 27.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.25 Mn |
| Mar 31, 2026 | 27.25 Mn |
| Dec 31, 2025 | 1.35 Mn |
| Dec 31, 2025 | 1.35 Mn |
| Sep 30, 2025 | 113.56 Mn |
| Sep 30, 2025 | 113.56 Mn |
| Jun 30, 2025 | 170.59 Mn |
| Jun 30, 2025 | 170.59 Mn |
| Mar 31, 2025 | 1.36 Mn |
| Mar 31, 2025 | 1.36 Mn |
| Dec 31, 2024 | -17,000.00 |
| Dec 31, 2024 | -17,000.00 |
| Sep 30, 2024 | 97.14 Mn |
| Sep 30, 2024 | 97.14 Mn |
| Jun 30, 2024 | 70.13 Mn |
| Jun 30, 2024 | 70.13 Mn |
| Mar 31, 2024 | 78.66 Mn |
| Mar 31, 2024 | 78.66 Mn |
| Dec 31, 2023 | 77,000.00 |
| Dec 31, 2023 | 77,000.00 |